- Global Operation
- Contract Manufacturing
Paxel® (Paclitaxel) is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Paxel® is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first line therapy, Paxel is indicated in combination with cisplatin.
Paxel® is indicated for the adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Paxel® is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracline unless clinically contraindicated.
Paxel® is indicated for the first line therapy of advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracline therapy is suitable or in combination with trastuzumab in patients who over express HER-2 at a 2+ or 3+ level as determined by immuno-histochemistry.
Gemcitabine, in combination of Paxel®, is indicated in the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Paxel® is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab, in patients who have tumors that over-express HER-2 and who have not received previous chemotherapy for their metastatic disease.
Non Small Cell Lung Carcinoma
Paxel®, in combination with cisplatin, is indicated for the first line treatment of non-small cell lung cancerin patients who are not candidates for potential curative surgery and/or radiation therapy.
Paxel® is indicated for the second line treatment of AIDS related Kaposi's Sarcoma.
Paxel® is indicated for the treatment of Gastric Carcinoma.
Paxel® Injection 30 mg: Each vial contains 5 ml solution containing Paclitaxel USP 30 mg (6 mg/ml).
Paxel® Injection 100 mg: Each vial contains 16.7 ml solution containing Paclitaxel USP 100 mg (6 mg/ml).
Paxel® Injection 300 mg: Each vial contains 50 ml solution containing Paclitaxel USP 300 mg (6 mg/ml).